Cascade of engagement in care (N = 986).

<p>Attending ≥ 8 groups sessions = completion of early recovery; Complete full 16 week program = completion of relapse prevention.</p

Correlates of treatment completion (N = 129).

<p>Correlates of treatment completion (N = 129).</p

Correlates of a negative urine toxicology result in last two weeks of treatment (N = 304).

<p>Correlates of a negative urine toxicology result in last two weeks of treatment (N = 304).</p

Risk Factors of Time to Treatment Failure.

1<p>All adjusted models include treatment condition.</p><p>Table Legend:</p><p>QOL_health: general health perceptions.</p><p>QOL_mental: mental health.</p

ACTG A5175/Pearls trial – Survival probability estimate from randomization to treatment failure by pill count non-adherence (solid line = did not miss any pills; dashed line = missed any pills).

<p>ACTG A5175/Pearls trial – Survival probability estimate from randomization to treatment failure by pill count non-adherence (solid line  =  did not miss any pills; dashed line  =  missed any pills).</p

Baseline Participant Characteristics.

<p>Table Legend:</p><p>QOL_health: general health perceptions.</p><p>QOL_mental: mental health.</p><p>Treatment: Once daily protease inhibitor + nucleoside reverse transcriptase inhibitors: atazanavir + didanosine-EC and emtricitabine.</p><p>Treatment: Once daily non-nucleoside reverse transcriptase inhibitor + nucleoside reverse transcriptase inhibitors: efavirenz + co-formulated emtricitabine-tenofovir-DF.</p><p>Standard of care: efavirenz plus co-formulated lamivudine-zidovudine.</p